MERIAN GLOBAL INVESTORS UK Ltd reduced its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 58.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 646,734 shares of the biopharmaceutical company’s stock after selling 916,260 shares during the quarter. MERIAN GLOBAL INVESTORS UK Ltd’s holdings in Halozyme Therapeutics were worth $10,412,000 at the end of the most recent quarter.
Several other hedge funds have also made changes to their positions in HALO. Rhumbline Advisers increased its holdings in Halozyme Therapeutics by 45.4% during the 4th quarter. Rhumbline Advisers now owns 179,099 shares of the biopharmaceutical company’s stock worth $2,620,000 after acquiring an additional 55,936 shares during the period. Arete Wealth Advisors LLC bought a new stake in Halozyme Therapeutics during the 4th quarter worth approximately $3,461,000. Verity Asset Management Inc. bought a new position in shares of Halozyme Therapeutics in the 4th quarter worth $297,000. Granite Investment Partners LLC increased its holdings in shares of Halozyme Therapeutics by 29.3% in the 4th quarter. Granite Investment Partners LLC now owns 988,939 shares of the biopharmaceutical company’s stock worth $14,468,000 after buying an additional 223,836 shares during the last quarter. Finally, Synovus Financial Corp increased its holdings in shares of Halozyme Therapeutics by 37.1% in the 4th quarter. Synovus Financial Corp now owns 47,926 shares of the biopharmaceutical company’s stock worth $702,000 after buying an additional 12,972 shares during the last quarter. Institutional investors own 81.66% of the company’s stock.
Shares of NASDAQ:HALO opened at $15.61 on Friday. Halozyme Therapeutics, Inc. has a one year low of $13.24 and a one year high of $19.56. The company has a quick ratio of 2.72, a current ratio of 2.95 and a debt-to-equity ratio of 0.07.
Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.01 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.01. The firm had revenue of $56.95 million for the quarter, compared to analyst estimates of $67.80 million. Halozyme Therapeutics had a negative net margin of 28.70% and a negative return on equity of 20.36%. The business’s revenue for the quarter was up 84.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.19) EPS. As a group, research analysts predict that Halozyme Therapeutics, Inc. will post -0.42 earnings per share for the current fiscal year.
A number of brokerages have recently commented on HALO. Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a report on Tuesday, January 29th. Cantor Fitzgerald reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, May 8th. BidaskClub lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, March 6th. ValuEngine lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, March 6th. Finally, TheStreet lowered shares of Halozyme Therapeutics from a “c” rating to a “d” rating in a report on Tuesday, March 5th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $20.40.
ILLEGAL ACTIVITY NOTICE: This story was first reported by Highlight Press and is the sole property of of Highlight Press. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://highlightpress.com/2019/05/19/merian-global-investors-uk-ltd-sells-916260-shares-of-halozyme-therapeutics-inc-halo.html.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Featured Article: What is a recession?
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.